RxDoctor Payments Data

Howard Blank, MD

Endocrinology, Diabetes & Metabolism · Farmington Hills, MINPI 1699787424

Payments from drug & device makers

$824in general payments, 2019–2025

Across 46 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$178
  • Abbott$174
  • Amgen$98
  • Insulet Corporation$75
  • Medtronic$74
  • Pfizer$70
  • plus $155 from 6 others

What the payments were for

  • Food & beverage$824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$824 in reported general payments places this provider in the 35th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan

Medicare billing

Part B allowed, 2024
$130,756
Medicare patients
508
Services billed
1,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide174$297,550
KorlymMifepristone13$262,210
OzempicSemaglutide123$233,841
TrulicityDulaglutide104$209,470
JardianceEmpagliflozin137$199,577
Teriparatide24$75,120
JanuviaSitagliptin Phosphate44$63,123
Humalog Kwikpen U-200Insulin Lispro22$61,959
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog42$41,531
Lantus SolostarInsulin Glargine,hum.Rec.Anlog230$39,464
Novolog FlexpenInsulin Aspart90$29,534
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/734$26,306
Fiasp FlextouchInsulin Aspart (Niacinamide)25$25,728
Tresiba Flextouch U-200Insulin Degludec27$24,637
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$22,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$178$240,273153 claims
PfizerLevoxyl$70$4,799157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

Other endocrinology, diabetes & metabolism in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →